Quick answer on AOD‑9604 for stubborn fat (TL;DR)
- Evidence in humans: No peer‑reviewed, placebo‑controlled trials demonstrate clinically meaningful fat loss with AOD‑9604.
- Regulatory status in Australia: Not approved by the TGA and not on the ARTG; advertising/supply are restricted. Access, if any, requires unapproved medicine pathways or a clinical trial.
- Sport: Prohibited by WADA as a non‑approved substance (S0) at all times.
- Alternatives with strong evidence: GLP‑1 and GLP‑1/GIP medicines (e.g., semaglutide, tirzepatide) show substantial, peer‑reviewed weight‑loss outcomes; tesamorelin reduces visceral fat in a defined indication.
What AOD‑9604 is — and why people ask about “stubborn fat”
AOD‑9604 is a synthetic fragment (176–191) of human growth hormone (hGH) developed to target fat metabolism without increasing IGF‑1. Preclinical work in animals suggested lipolytic effects, which led to interest for “stubborn fat.” However, translating early animal signals to reliable, clinically meaningful fat loss in humans requires well‑designed randomised controlled trials (RCTs).
What the human evidence shows
To date, there are no peer‑reviewed RCTs in the scientific literature demonstrating clinically meaningful reductions in body weight or specific “stubborn” fat compartments with AOD‑9604 in the general adult population.
Sponsor‑run Phase 2 obesity studies were conducted but did not proceed to successful registration, and public communications indicated failure to meet primary weight‑loss endpoints. Clinical trial registrations document short‑term studies (generally weeks to a few months) assessing oral AOD‑9604 in adults with overweight or obesity; however, peer‑reviewed efficacy publications are lacking, and available summaries do not show superiority over placebo on weight outcomes.
- ClinicalTrials.gov records for AOD‑9604 trials describe obesity studies with multiple oral dose arms over several weeks to 12 weeks; no posted peer‑reviewed results demonstrating clinically relevant weight loss versus placebo are available (see example registry entries below).
- Safety/PK reports indicate no stimulation of the GH/IGF‑1 axis at studied doses, but efficacy for weight reduction was not established in humans.
Authoritative sources and registries:
- ClinicalTrials.gov — “AOD9604” search overview: https://clinicaltrials.gov/search?cond=Obesity&term=AOD9604
- WADA statement clarifying non‑approval and prohibition status (2013): https://www.wada-ama.org/en/news/wada-statement-regarding-aod-9604
Safety considerations and unknowns
- Regulatory non‑approval means quality, strength and purity can vary when sourced outside regulated pathways. This increases the risk of contamination or mislabelled products.
- Human safety data are limited and largely short term; long‑term effects and interactions remain insufficiently characterised.
- Athletes: Use is prohibited in sport (WADA S0). A doping violation can occur regardless of intent.
Australian legality: how TGA rules apply to AOD‑9604
In Australia, AOD‑9604 is not approved by the Therapeutic Goods Administration (TGA) and does not appear on the Australian Register of Therapeutic Goods (ARTG). As an unapproved medicine, it cannot be generally supplied or advertised to the public as a therapeutic good. Any lawful medical access requires specific pathways:
- Special Access Scheme (SAS) or Authorised Prescriber pathways for unapproved medicines
- Ethics‑approved clinical trials
Key official resources:
- TGA: Accessing unapproved therapeutic goods (SAS, Authorised Prescriber, Clinical Trials) — https://www.tga.gov.au/how-we-regulate/unapproved-therapeutic-goods/access-unapproved-therapeutic-goods
- TGA ARTG search (to check if a product is registered) — https://www.tga.gov.au/resources/artg
- TGA: Advertising health products in Australia (restrictions for unapproved medicines) — https://www.tga.gov.au/resources/resource/guidance/advertising-health-products-australia
Is AOD‑9604 allowed in sport?
No. The World Anti‑Doping Agency (WADA) prohibits non‑approved substances under category S0 at all times. WADA explicitly confirmed in 2013 that AOD‑9604 is prohibited.
- WADA statement on AOD‑9604 (2013): https://www.wada-ama.org/en/news/wada-statement-regarding-aod-9604
- Current WADA Prohibited List: https://www.wada-ama.org/en/prohibited-list
Alternatives with stronger evidence for “stubborn fat” and weight loss
If you are considering AOD‑9604 for persistent abdominal or visceral fat, discuss proven therapies first. High‑quality randomised trials show:
- Semaglutide (GLP‑1): Mean ~14.9% body‑weight loss at 68 weeks vs 2.4% with placebo, alongside lifestyle support (STEP 1, adults with obesity). NEJM 2021 — https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Tirzepatide (GIP/GLP‑1): Up to ~20.9% mean weight loss at 72 weeks in SURMOUNT‑1 (non‑diabetic adults with obesity). NEJM 2022 — https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Tesamorelin: Significant reductions in visceral adipose tissue for HIV‑associated lipodystrophy. NEJM 2010 — https://www.nejm.org/doi/full/10.1056/NEJMoa0907646
Learn more:
Who might talk to a doctor — and what to ask
- If abdominal or visceral fat persists despite diet, activity and sleep optimisation
- If you meet criteria for evidence‑based pharmacotherapy for weight management
- If you are considering any unapproved substance you saw online
Questions to bring:
- Am I eligible for approved weight‑loss medicines with strong evidence?
- What work‑up do I need to assess cardiometabolic risk?
- How do Australian regulations affect access and safety?
Key references and official documents
- WADA statement regarding AOD‑9604 (2013) — https://www.wada-ama.org/en/news/wada-statement-regarding-aod-9604
- WADA Prohibited List — https://www.wada-ama.org/en/prohibited-list
- TGA: Accessing unapproved therapeutic goods — https://www.tga.gov.au/how-we-regulate/unapproved-therapeutic-goods/access-unapproved-therapeutic-goods
- TGA ARTG public search — https://www.tga.gov.au/resources/artg
- TGA: Advertising health products in Australia — https://www.tga.gov.au/resources/resource/guidance/advertising-health-products-australia
- Semaglutide for weight management (STEP 1) — NEJM 2021 — https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Tirzepatide for weight management (SURMOUNT‑1) — NEJM 2022 — https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Tesamorelin and visceral fat in HIV — NEJM 2010 — https://www.nejm.org/doi/full/10.1056/NEJMoa0907646
- ClinicalTrials.gov search for “AOD9604” — https://clinicaltrials.gov/search?cond=Obesity&term=AOD9604
Frequently asked questions
Does AOD‑9604 reduce stubborn fat in humans?
There are no peer‑reviewed, placebo‑controlled human trials showing clinically meaningful reductions in “stubborn fat” or total body weight with AOD‑9604.
Is AOD‑9604 legal to buy in Australia?
AOD‑9604 is not TGA‑approved and is not on the ARTG. General supply or advertising as a therapeutic good is restricted. Any lawful medical access requires unapproved medicine pathways (SAS/Authorised Prescriber) or a clinical trial.
Is AOD‑9604 banned in sport?
Yes. WADA prohibits non‑approved substances (S0), and specifically confirmed that AOD‑9604 is prohibited.
What are better‑supported options for persistent abdominal fat?
GLP‑1 and GLP‑1/GIP medicines (semaglutide, tirzepatide) have robust RCT evidence for significant weight loss; tesamorelin reduces visceral fat in an approved, specific clinical setting.
Will AOD‑9604 affect IGF‑1 like growth hormone?
Available short‑term human data suggest no meaningful stimulation of the GH/IGF‑1 axis at studied doses, but this does not establish weight‑loss efficacy or long‑term safety.
Where can I read official rules and guidance?
See the TGA’s guidance on unapproved medicines and the WADA Prohibited List. Links are provided in the references above.
Authors and medical review
Author: James Cartwright — Health writer focused on peptides, weight management and Australian access pathways.
Medical reviewer: Dr Sarah Bennett, MBBS, FRACGP — GP with an interest in metabolic health and therapeutics regulation in Australia.
Published: 1 Nov 2024 • Updated: 18 Apr 2026
Ask a clinician — get help with safer, proven options
We aim to reply within 1–2 business days.
Takeaway
For the query “aod 9604 for stubborn fat,” current human evidence does not support meaningful fat‑loss benefits, and the substance is unapproved in Australia and prohibited in sport. Discuss regulated, trial‑proven options with a qualified clinician.